Northern Territory of Australia

Medicines, Poisons and Therapeutic Goods Act 2012

Top End Health Service Sexual Assault Referral Centres Treatment Protocols Revocation and Approval

I, Christine Maree Connors, Acting Chief Health Officer:

(a) under section 254(5) of the Medicines, Poisons and Therapeutic Goods Act 2012, (the

Act), revoke the instrument titled "Top End Health Service Sexual Assault Referral

Centres Declarations and Approval" dated 27 July 2017 and published in Gazette No.

S56 of 2 August 2017; and

(b) under section 254(1) of the Act, approve each Scheduled substance treatment protocol

specified in Schedule A;

(c) under section 254(3) of the Act, state that each Schedule substance treatment protocol

specified in Schedule A remains in effect for a period of 2 years on and from the date

of this instrument.

Dated 14 March 2023 @ 10:48am

Acting Chief Health Officer

Schedule A

Title	Publication Date	Author	
Sexual Assault Referral	10 March 2023	Sexual Health and Blood	
Centres (SARC) Treatment		Borne Virus Unit, Northern	
Protocol		Territory Government,	
		Department of Health	

Sexual Assault Referral Centres (SARC) Treatment Protocol

Areas Applicable	NT Wide - All Sexual Assault Referral Centres (SARC) including outreach clinics operated by SARC		
Health Professionals authorised by this SSTP	Nurses Midwives Aboriginal and Torres Strait Islander Health Practitioners		
Scheduled Subst ance(s)	Amoxicillin Probenecid Azithromycin Benzathine Benzylpenicillin Ceftriaxone Lidocaine Doxycycline Hepatitis B Vaccination Levonorgestrerol Metoclopramide Metronidazole Tetanus Toxoid Vaccination Trimethoprim Ibuprofen Salbutamol		
Indication	As per Sexual Health and Blood Borne Virus Unit SSTPs and NIM Protocols - (HEALTHINTRA-1880-2608)		
Contraindications and/or Exclusions*	As per Sexual Health and Blood Borne Virus Unit SSTPs and NIM Protocols - (HEALTHINTRA-1880-2608)		
Dose and Route*	As per Sexual Health and Blood Borne Virus Unit SSTPs and NIM Protocols - (HEALTHINTRA-1880-2608)		
Administration	As per Sexual Health and Blood Borne Virus Unit SSTPs and NIM Protocols - (HEALTHINTRA-1880-2608)		
Dose Frequency*	As per Sexual Health and Blood Borne Virus Unit SSTPs and NIM Protocols - (HEALTHINTRA-1880-2608)		
Drug Interactions*	As per Sexual Health and Blood Borne Virus Unit SSTPs and NIM Protocols - (HEALTHINTRA-1880-2608)		
Monitoring requirements*	As per Sexual Health and Blood Borne Virus Unit SSTPs and NIM Protocols - (HEALTHINTRA-1880-2608)		



Accreditation Requirements	 Nurses Hold registration with the Nursing and Midwifery Board of Australia as a Nurse with no conditions, notations or undertakings which may limit delivery of clinical services directly to patients 			
	Midwives Hold registration with the Nursing and Midwifery Board of Australia with no conditions or undertakings which may limit delivery of clinical services.			
	_	lander Health Practitioners (ne Aboriginal and Torres Str Istralia with no conditions o	ait Islander Health	
	limit delivery of clinical services directly to patients All health professionals following this protocol must:			
	 Hold a current Basic Life Support Certificate or Provide First Aid Certificate and provide documentary evidence of the qualifications when required Maintain continuing professional development related to skills and competencies required for delivery of medicines. Have completed essential training requirements in line with the Essential Training Policy relevant to their employment Have completed the SARC Darwin Medication Learning Package & Questionnaire. 			
Documentation (including necessary information to the patient)	As per Sexual Health and Blood Borne Virus Unit SSTPs and NIM Protocols - (HEALTHINTRA-1880-2608)			
Related Documents	As per Sexual Health and Blood Borne Virus Unit SSTPs and NIM Protocols - (HEALTHINTRA-1880-2608)			
Chief Health Officer	Signature	Name	Date	
		Dr Christine Connors	14/03/2023	
Period of effect	This SSTP is in effect from time of publishing on Agency website until 14/03/2025			

References:

^{*} The drug information provided is to act as a guide to outline the limits of legal dealing with the named scheduled substances. Further information reference should be made to the full manufacturer's product info and other reliable sources of medicines information. If contraindications or interactions are present refer to medical officer before administration